choline transporter 1  (Proteintech)

Journal: CNS Neuroscience & Therapeutics

Article Title: Electroacupuncture regulates Rab5a‐mediating NGF transduction to improve learning and memory ability in the early stage of AD mice

doi: 10.1111/cns.14743

Figure Lengend Snippet: The expression levels of cholinergic‐related proteins in the basal forebrain and hippocampus. (A–E) The expression levels of vAchT (A), ChT1 (B), AchE (C), m1AchR (D), and m2AchR (E) in the basal forebrain after EA intervention. (F‐J) The expression levels of vAchT (F), ChT1 (G), AchE (H), m1AchR (I), and m2AchR (J) in the hippocampus after EA intervention ( n = 6 for each group, ** p < 0.01/*** p < 0.001 vs WT group, # p < 0.05/## p < 0.01/### p < 0.001 vs AD group, && p < 0.01 vs EA group). (K) Greyscale image of proteins. vAchT, vesicular acetylcholine transporter; ChT1, Choline transporter; AchE, enzyme acetylcholinesterase; m1AchR, Type‐1 muscarinic Acetylcholine receptor; m2AchR, Type‐2 muscarinic Acetylcholine receptor.

Article Snippet: The membranes were incubated with primary antibodies at 4°C: Rab5a (1:1000; 24 h, CST, E6N8S); Rabep1 (1:5000; 24 h, Abcam, ab176578); TrkA (1:300; 36 h, Abcam, ab216626); pTrkA (1:500; 36 h, Invitrogen, PA5‐37672); AKT (1:1000; 24 h, CST, #4691); pAKT (1:1000; 36 h, CST, #4060); ERK (1:5000; 24 h, Abcam, ab184699); pERK (1:2000; 24 h, CST, #4370); ChAT (1:5000; 24 h, Abcam, ab181023); AchE (1:5000; 36 h, Abcam, ab183591); vAchT (1:1000; 36 h, Sigma, sab4200559); ChT1 (1:5000; 24 h, Abcam, ab154186); m1AchR (1:1000; 36 h, boster, BA1543); m2AchR (1:5000; 24 h, Abcam, ab109226); GAPDH (1:5000; 24 h, Proteintech, 60,004–1‐1 g); and β‐actin (1:5000; 24 h, Proteintech, 66,009–1‐1 g).

Techniques: Expressing

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: CircFBXW4 Suppresses Colorectal Cancer Progression by Regulating the MiR-338-5p/SLC5A7 Axis.

doi: 10.1002/advs.202300129

Figure Lengend Snippet: Figure 7. CircFBXW4 regulates SLC5A7 expression by acting as a sponge for miR-338-5p. A) Relative expression of candidate mRNAs in SW480 cells transfected with the miR-338-5p mimic. B) Relative expression of candidate mRNAs in SW620 cells transfected with the miR-338-5p inhibitor. C) Relative protein levels of SLC5A7 in CRC cells transfected with the miR-338-5p mimic or inhibitor. D) The relative expression of SLC5A7 in CRC tissues and matched adjacent normal tissues was determined by qRT‒PCR (n = 40). E) Pearson correlation analysis between the expression levels of miR-338-5p and SLC5A7 in our own patient cohort (n = 40). F) Schematic illustration of the SLC5A7-WT and SLC5A7-MUT luciferase reporter vectors. G) Relative luciferase activity was measured in 293T cells after cotransfection with SLC5A7-WT or SLC5A7-MUT and the miR-338-5p mimic or NC. H) The relative mRNA and protein expression levels of SLC5A7 were measured by qRT‒PCR and western blotting in SW480 cells transfected with si-NC or si-circFBXW4 with or without the miR-338-5p inhibitor. I) The relative mRNA and protein levels of SLC5A7 were measured by qRT‒PCR and western blotting in SW620 cells transfected with vector or the circFBXW4-OE plasmid with or without the miR-338-5p mimic. The data are shown as the means ± SDs; *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: The primary antibodies used to detect Ki-67, PCNA, and Caspase3 were purchased from ABclonal (China), and the primary antibody used to detect SLC5A7 was purchased from ProteinTech (China).

Techniques: Expressing, Transfection, Luciferase, Activity Assay, Cotransfection, Western Blot, Plasmid Preparation